“行气散瘀”针刺法对 POCI 患者脑血流调控的临床研究

注册号:

Registration number:

ChiCTR1900027654 

最近更新日期:

Date of Last Refreshed on:

2019-11-23 11:32:03 

注册时间:

Date of Registration:

2019-11-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

“行气散瘀”针刺法对 POCI 患者脑血流调控的临床研究

Public title:

Effect of acupuncture on cerebral blood flow in patients with posterior circulation infarction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

脑血管疾病防治技术研究

Scientific title:

Prevention and treatment of cerebrovascular diseases

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李波漩 

研究负责人:

李琛 

Applicant:

Boxuan Li 

Study leader:

Chen Li 

申请注册联系人电话:

Applicant telephone:

+86 13820507166

研究负责人电话:

Study leader's
telephone:

+86 13502101670

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lbx0632@163.com

研究负责人电子邮件:

Study leader's E-mail:

wendy7626@sina.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国天津市西青区昌凌路 88 号

研究负责人通讯地址:

中国天津市西青区昌凌路 88 号

Applicant address:

88 Changling Road, Xiqing District, Tianjin, China

Study leader's address:

88 Changling Road, Xiqing District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津中医药大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

研究负责人所在单位:

天津中医药大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TYLL2019[K]字 004

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

天津中医药大学第一附属医院伦理委员会

Name of the ethic committee:

IEC of The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

贾景蕴

Contact Name of the ethic committee:

Jingyun Jia

伦理委员会联系地址:

中国天津市西青区昌凌路 88 号

Contact Address of the ethic committee:

88 Changling Road, Xiqing District, Tianjin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津中医药大学第一附属医院

Primary sponsor:

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

中国天津市西青区昌凌路 88 号

Primary sponsor's address:

88 Changling Road, Xiqing District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院

具体地址:

中国天津市西青区昌凌路 88 号

Institution
hospital:

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Address:

88 Changling Road, Xiqing District, Tianjin, China

经费或物资来源:

天津市卫生和计划生育委员会

Source(s) of funding:

Tianjin Municiple Health Commission

研究疾病:

后循环梗死  

Target disease:

Posterior circulation infarction

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察“行气散瘀”针刺法治疗 POCI 的临床疗效,为 POCI 治疗提供行之有效的治疗方案和循证依据,形成适宜推广的针刺治疗新技术。  

Objectives of Study:

The main purposes of this clinical trial are to observe the clinical efficacy of acupuncture in treating POCI, and provide effective treatment options and basic data for future clinical studies.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①合并脑出血患者;
②椎动脉狭窄率>70%的患者;
③病情危重或术后;
④具有合并重大心、肺、肝、肾及患有原发性造血系统疾病者;
⑤具有传染病、皮肤病者;
⑥易引起晕针者;
⑦妊娠期或哺乳期者;
⑧不能按照医生规定服药及治疗,无法进行试验者;
⑨正在参加另一项试验者

Exclusion criteria:

1. Hemorrhagic stroke;
2. Vertebral artery stenosis rate > 70%;
3. Critical illnesses that require operation;
4. Severe heart heart, liver, or kidney diseases, severe hematopoietic system conditions;
5. Infectious disease or skin disease;
6. Oversensitivity to acupuncture;
7. Pregnancy or lactation;
8. Inability to cooperate with the treatment;
9. Participation in another current clinical trial.

研究实施时间:

Study execute time:

From 2019-06-01 00:00:00 To 2021-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-12-01 00:00:00 To 2020-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

100

Group:

experimental group

Sample size:

干预措施:

“行气散瘀”针刺

干预措施代码:

Intervention:

acupuncture

Intervention code:

组别:

试验组

样本量:

100

Group:

experimental group

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

basic treatments for ischemic stroke

Intervention code:

组别:

对照组

样本量:

100

Group:

control group

Sample size:

干预措施:

常规治疗

干预措施代码:

Intervention:

basic treatments for ischemic stroke

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院 

单位级别:

三级甲等 

Institution
hospital:

First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第二附属医院 

单位级别:

三级甲等 

Institution
hospital:

Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市中医药研究院附属医院 

单位级别:

三级甲等 

Institution
hospital:

Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市滨海新区中医医院 

单位级别:

二级甲等医院 

Institution
hospital:

Binhai New Area Hospital of Traditional Chinese Medicine . Tianjin

Level of the institution:

Secondary A Hospital

国家:

中国

省(直辖市):

天津 

市(区县):

 

Country:

China

Province:

Tianjin

City:

单位(医院):

天津市北辰区中医医院 

单位级别:

三级甲等 

Institution
hospital:

Beichen District Hospital of Traditional Chinese Medicine . Tianjin

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

经颅彩色多普勒

指标类型:

主要指标

Outcome:

Transcranial doppler

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血浆5-羟色胺含量

指标类型:

主要指标

Outcome:

Serotonin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

去甲肾上腺素

指标类型:

主要指标

Outcome:

Norepinephrine

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国国立卫生研究院卒中量表

指标类型:

主要指标

Outcome:

National institutes of health stroke scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日常生活能力量表

指标类型:

主要指标

Outcome:

Activity of Daily Living Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

一般资料

指标类型:

次要指标

Outcome:

general data

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

次要指标

Outcome:

liver function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

次要指标

Outcome:

renal function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心电图

指标类型:

次要指标

Outcome:

electrocardiogram

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本课题随机化方法采用多中心临床中央随机,五个中心的合格患者将通过中央随机分配系统以1:1的比例随机分配到实验组或对照组,随机数和组划分将发送到针灸师的电话中。

Randomization Procedure (please state who generates the random number sequence and by what method):

Eligible patients in five centers will be randomly assigned to experimental group or control group in a 1:1 ratio via a central randomization system.The random number and group division will be sent to acupuncturist's phone.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

文章及论文的发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publication of articles and papers

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据管理人员负责建立统一的数据库,专门研究人员收集、录入数据至病例报告表;由本单位的数据管理人员将病例报告表输入数据库。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data manager is responsible for establishing a unified database,and specialized researchers will collect and enter data into CRF; The data manager will enter the case report form into the database.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-11-23 11:32:03